Assay News and Research

RSS

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

QR Pharma, Inc. (QR) and Massachusetts General Hospital announced today a new collaborative research agreement to work on a treatment for Parkinson's disease (PD).

17 Jun 2010

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

SQI Diagnostics Inc., a medical systems company focused on evolving laboratory-based biomarker testing, today announced that Gamma-Dynacare Medical Laboratories, one of Canada's largest providers of laboratory services, has agreed to put into operation SQI's SQiDworks(TM) platform, and to purchase SQI's multiplexed IgXplex(TM) Rheumatoid Arthritis consumables to meet its commercial needs.

17 Jun 2010

Predictive Biosciences completes $25M Series C financing round

Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced the completion of a $25 million Series C round of growth capital financing. New investor ProQuest Investments led the round, joined by all current investors: Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

16 Jun 2010

Vitro, HemoGenix launch new stem cell testing products at International Society for Stem Cell Research meeting

Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.

16 Jun 2010

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.

16 Jun 2010

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Amorfix Life Sciences, a company focused on the development of therapeutic monoclonal antibodies and diagnostics for the treatment of fatal neurodegenerative diseases and cancer, today announced its operational and financial results for the year ended March 31, 2010, as well as financial results for the fourth quarter.

11 Jun 2010

WaferGen announces microRNA, oncology gene panels for SmartChip Real-Time PCR System

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability.

10 Jun 2010

QuantRx Biomedical completes clinical testing of Q-Reader thyroid testing system

QuantRx Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that it has completed clinical testing of the Q-Reader thyroid testing system.

9 Jun 2010

Correlogic Systems' OvaCheck blood test for detection of epithelial ovarian cancer receives CE Mark

Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians.

9 Jun 2010

Takeda Rika Kogyo to distribute WaferGen's SmartChip Real-Time PCR System in Japan

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today announced the signing of an exclusive distribution agreement for the company's SmartChip Real-Time PCR System with Takeda Rika Kogyo Co., Ltd., a leading distributor of innovative products and services in the life science markets within Japan.

8 Jun 2010

Clarient granted U.K. patent for TLE3 biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy.

8 Jun 2010

Quintiles announces comprehensive suite of PI3K biomarker assays

Quintiles today announced a comprehensive suite of biomarker assays to help biopharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.

8 Jun 2010

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

Managing Myeloma launches MTR tool to help practitioners treat patients with multiple myeloma

Managing Myeloma is pleased to announce the launch of the Myeloma Treatment Resource at the annual American Society of Clinical Oncology meeting in Chicago. The MTR, developed by the Managing Myeloma multidisciplinary scientific advisors, is a compilation of convenient, unique tools and resources essential for practitioners treating patients with multiple myeloma.

7 Jun 2010

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

7 Jun 2010

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).

7 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

Assay News and Research

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

Predictive Biosciences completes $25M Series C financing round

Vitro, HemoGenix launch new stem cell testing products at International Society for Stem Cell Research meeting

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

WaferGen announces microRNA, oncology gene panels for SmartChip Real-Time PCR System

QuantRx Biomedical completes clinical testing of Q-Reader thyroid testing system

Correlogic Systems' OvaCheck blood test for detection of epithelial ovarian cancer receives CE Mark

Takeda Rika Kogyo to distribute WaferGen's SmartChip Real-Time PCR System in Japan

Clarient granted U.K. patent for TLE3 biomarker

Quintiles announces comprehensive suite of PI3K biomarker assays

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Managing Myeloma launches MTR tool to help practitioners treat patients with multiple myeloma

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News